Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Gynecologic 2

Conditions

Triple Negative Breast Neoplasms 5Neoplasms 5Breast Neoplasms 5Recurrence 2Ovarian Neoplasms 2Hypersensitivity 2Brain Neoplasms 2Squamous Cell Lung Cancer 1Solid Tumors 1Neoplasm Metastasis 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × iniparib × Clear all
NCT00422682 2016-06-10

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
136 enrolled
Tumor-Agnostic

Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
41 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
43 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT00298675 2012-08-02

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡